Clinical Trial

Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the clinical safety and preliminary efficacy of CEA specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene in the treatment of stage IV gastric cancer patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2015-07-09.
Status change: Not Yet Recruiting → Active, Not Recruiting 2016-02-19
Trial Details
NCT Number NCT02496273
Lead Sponsor The First People's Hospital of Changzhou
Conditions Gastric Cancer
Enrollment 60 participants
Start Date 2016-01
Primary Completion 2026-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2016-02-22